Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.



Bullboard - Investor Discussion Forum NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

NurExone Biologic Inc. is a pharmaceutical company. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active... see more

TSXV:NRX - Post Discussion

NurExone Biologic Inc. > 2025 Is The Critical Year For FDA Approval!
View:
Post by javaman12 on Jan 14, 2025 10:25pm

2025 Is The Critical Year For FDA Approval!

A near term 'Investigational New Drug' (IND) submission will be quickly followed by Phase I/IIa Human trials to help wheel chair bound victims get up and walking once again! After the IND submission and approval, Phase 1 trials can commence as early as 30 days later!

https://globalregulatorypartners.com/wp-content/uploads/Presentation-1-Overview-of-FDA-Requirements-for-IND-16Feb2020-new-1.pdf

NurExone is on the march! Strike up the band! A time of great celebration time is coming our way!

https://media.stockhouse.com/media/companies/v-nrx/eqp/NurExone-Corporate-Presentation-v3-151024.pdf#EQP_SB-PRESENTATION_20241031

Preclinical animal studies have already been done with a 75% success rate. Humans with a new found hope would be strongly motivated to take a greater advantage of physiotherapy strategies to help them get up and walk better to rejoin all the rest of the crowd! 

How exciting would that be for them? 

This new modern miracle is on its way!

Spinal cord injuries won't need to lock human beings into a wheel chair bound existence for the rest of their lives! That is a new hope that they have never had before!

                                               May the crippled walk once again!

                                    The intial 2025 clinical trials are now set to begin!

                                                        All  the best! Java
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.NRX



Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.



The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu